Genmab gains as Goldman upgrades stock to Buy on increased pipeline confidence

The upgrade is less about near-term upside in Genmab and more about a market regime shift: the stock is moving from a single-royalty comp to a multi-shot pipeline story. That matters because the marginal buyer can now underwrite a staggered sequence of data events through 2H26, which compresses perceived binary risk and typically supports a higher multiple well before revenue inflects. In other words, the catalyst path is now visible enough to pull forward de-risking into the stock long before any of the readouts hit.

The bigger second-order effect is on the competitive set in antibody-drug conjugates and bispecifics. If Rina-S and petosemtamab continue to look differentiated, late-stage competitors in gyn-onc and head-and-neck will face a tougher financing and partnering environment, because Genmab’s valuation can become a public-market reference point for what “good” looks like in these modalities. That can also pressure smaller peers with similar mechanisms but weaker data packages, since capital tends to re-rate to the best-in-class read-through rather than the broad space.

The contrarian issue is that the market may be too focused on peak-sales math and not enough on pathway risk and timing slippage. Even if accelerated approval is delayed, the DCF hit is limited, but the stock can still derate on timeline drift if the 2H26 cadence slips into 2027; biotech multiples are highly sensitive to visible event density. Separately, the 2029 royalty fade is a longer-duration headwind that likely caps upside in the absence of a sustained multiple expansion, so this is still a story of asset optionality rather than clean earnings compounding.